INTRODUCTION
============

Cancer represents a leading cause of death worldwide ([@b53-bt-26-335]). Sex plays a crucial role in the incidence, disease prognosis and mortality in a variety of cancers ([@b64-bt-26-335]). The incidence of cancer was about 20% higher in men than in women and the mortality rate was 40% higher in men in the United States from 2009 to 2013 ([@b65-bt-26-335]). Sex differences influence cancer susceptibility at the genetic/molecular levels. Sex hormones also negatively or positively affect the development of various cancers. Biological specificities determine the outcome and response to therapy of cancer.

During the last decades, animal studies and clinical trials used males alone and excluded females ([@b36-bt-26-335]; [@b5-bt-26-335]; [@b79-bt-26-335]). Altered sex hormones in the menstrual cycle affect the experimental results ([@b5-bt-26-335]). In addition, the 1977 United States Food and Drug Administration guideline excluded women in clinical research due to the risk of birth defects ([@b48-bt-26-335]). Similar doses were administered to men and women in clinical chemotherapy ([@b33-bt-26-335]). Accumulating evidence shows sex-specific differences in toxicity and efficacy of chemotherapy ([@b69-bt-26-335]; [@b54-bt-26-335]; [@b1-bt-26-335]; [@b12-bt-26-335], [@b62-bt-26-335]). Especially, women experience higher adverse drug reactions to most anticancer drugs than men ([@b72-bt-26-335]).

This review summarized studies involving sex differences in epidemiology, sex hormones, and genetic/molecular factors. In addition, we reviewed sex-related differences in chemotherapy using anticancer agents such as 5-fluorouracil (FU), paclitaxel, doxorubicin, cisplatin, bevacizumab and rituximab. This article provides important clues and insights for the precise understanding of sex-specific differences in cancer.

SEX DIFFERENCES IN INCIDENCE AND MORTALITY OF CANCER
====================================================

Growing evidence shows sex-specific differences in the incidence and mortality associated with various cancers. Prostate, lung, and colorectal cancer occur the most in males, while breast, lung, and colorectal cancer are predominant in females in the United States ([@b64-bt-26-335]). In addition to the incidence of cancer in sex-specific organs such as prostate and ovary, sex differences in cancers such as colon, lung, and liver have been reported ([@b18-bt-26-335]; [@b68-bt-26-335]). Thyroid cancer incidence is much higher in females than in males ([@b18-bt-26-335]). Cancer incidence involving colorectal, stomach and liver cancer is higher in males than in females ([@b3-bt-26-335]). Furthermore, bladder cancer and leukemia have been predominantly diagnosed in males than in females ([@b25-bt-26-335]). In patients with colorectal cancer, women developed right-sided malignancy while men manifested the disease more on the left side ([@b37-bt-26-335]). Right-sided colon cancer is associated with a higher severity of cancer compared with left-sided disease ([@b37-bt-26-335]). The cause of disparity in location might be due to differences in estrogen level between men and women.

The mortality of cancer is reported to be greater in men than in women ([@b64-bt-26-335]). Especially, lung, colorectal and stomach cancers, which are the leading causes of cancer deaths, show higher mortality in men than in women ([@b64-bt-26-335]; [@b25-bt-26-335]). Female cancers such as breast, ovarian and uterine corpus cancer result in relatively high mortality ([@b64-bt-26-335]; [@b25-bt-26-335]). Men-specific cancers such as prostate cancer also represent prominent causes for cancer death ([@b64-bt-26-335]). Mortality associated with esophagus, liver, and bladder cancer is higher in men than in women ([@b64-bt-26-335]). Men had a 34% higher risk of death due to melanoma compared with women ([@b14-bt-26-335]). Therefore, mortality from various cancer types shows sex disparity.

Lung cancer was the leading cause of cancer death in men in 20th century due to smoking ([@b64-bt-26-335]). Lung cancer death was decreased by reduced smoking rates and early detection and treatment from 1991 to 2012 ([@b64-bt-26-335]). In both sexes, mortality due to gastric cancer declined rapidly in the 1930s in U.S ([@b64-bt-26-335]). Although the cause of dramatic reduction is not completely understood, the control of *Helicobacter pylori* infection, and better methods of food preservation resulted in a reduction of mortality due to stomach cancer ([@b7-bt-26-335]; [@b64-bt-26-335]).

SEX DIFFERENCES IN GENETIC AND MOLECULAR BASIS OF CANCER
========================================================

In genetic and molecular studies, susceptibility to disease varies across the sexes. Genetic and molecular disparities between males and females contribute to differences in the incidence of a variety of cancers. Men show a higher incidence of bladder cancer than women ([@b64-bt-26-335]). The lower incidence of bladder cancer in women was correlated with the sulfotransferase 1A1 (SULT1A1) Histidine (His) genotype ([@b78-bt-26-335]). Genetic polymorphism of SULT1A1 showed alteration from Arginine to His, which was triggered by A-to-G transition ([@b55-bt-26-335]). It was reported that the His213 allele genotype SULT1A1 significantly decreased the risk of bladder cancer exclusively in women ([@b78-bt-26-335]). Therefore, this gene might be associated with a protective role in women diagnosed with bladder cancer ([@b18-bt-26-335]).

Genetic polymorphism, which is linked to drug metabolizing enzymes, influences the risk of carcinogenesis ([@b10-bt-26-335]). For example, acute leukemia has a higher rate of incidence in men than in women ([@b10-bt-26-335]). It was reported that men with deletion of glutathione s-methyltransferase T1 (GSTT1), which is a glutathione s-methyltransferase polymorphism, underwent phase 2 metabolism and detected frequently in acute lymphoblastic leukemia (ALL) than men with normal GSTT1 ([@b46-bt-26-335]; [@b30-bt-26-335]; [@b10-bt-26-335]). Deletion of GSTT1 gene abrogated the enzyme activity ([@b2-bt-26-335]).

NAD(P)H:quinone oxidoreductase 1 (NQO1) catalyzes free radical detoxification ([@b70-bt-26-335]). NQO1 polymorphism with substitution of C to T base pair at position 609 of NQO1 decreases the activity of the enzyme ([@b4-bt-26-335]; [@b22-bt-26-335]). NQO1 polymorphism showed a higher incidence of ALL only in males, but not in females ([@b10-bt-26-335]).

Murine double minute 2 (MDM2) downregulates the expression of p53 protein, a tumor suppressor ([@b19-bt-26-335]; [@b8-bt-26-335]). A single nucleotide polymorphism 309 (SNP 309) in MDM2 promotor increases the affinity of the transcriptional activator Sp1, which enhances the expression of MDM2 and consequently leads to attenuation of p53 pathway ([@b8-bt-26-335]). Attenuation of p53 DNA damage response occurs in the presence of both wild-type allele of p53 and G-allele of SNP 309 ([@b9-bt-26-335]). In addition, estrogen signaling affects the level of MDM2 ([@b9-bt-26-335]). In the diffuse large B-cell lymphoma (DLBCL), sporadic soft-tissue sarcoma, and highly invasive estrogen receptor-positive ductal carcinoma, estrogen signaling pathway increases tumor formation directly or indirectly in women carrying the Gallele of SNP309 ([@b9-bt-26-335]). Taken together, genetic and molecular differences might influence the disparity of the risk of cancer between men and women.

SEX DIFFERENCES IN SEX HORMONES IN CANCER INCIDENCE
===================================================

Sex hormones might contribute to differences in the incidence of cancer between men and women ([@b16-bt-26-335]; [@b18-bt-26-335]). ALL is more likely to occur in men because of limited estrogen level ([@b16-bt-26-335]). Estrogen plays a role in the inhibition of nuclear factor kappa B (NF-κB). NF-κB regulates the transcription of interferon regulatory factor 4 (IRF4) ([@b16-bt-26-335]). IRF4 is involved in the differentiation of B and T cells and is overexpressed in B-cell malignancies as a result of NF-κB hyperactivation ([@b16-bt-26-335]). IRF4 polymorphisms are related with the incidence of ALL ([@b16-bt-26-335]). Thus, a combination of intronic polymorphism of IRF4 and lack of estrogen might predispose men to leukemia.

Estrogen is linked closely to a higher rate of thyroid cancer development in women ([@b38-bt-26-335]; [@b18-bt-26-335]). Estrogen increases the proliferation of human thyroid papillary carcinoma cell line and promotes the expression of B-cell lymphoma-extra large (Bcl-XL), which is known as an anti-apoptotic protein ([@b31-bt-26-335]; [@b38-bt-26-335]), compared with testosterone. Endogenous female sex hormone such as progestin increase excretion of bile acid, which has been suggested as a potential inducer of colon cancer ([@b47-bt-26-335]; [@b23-bt-26-335]). Exogenous estrogen decreased the production of secondary bile acid which is responsible for promoting malignant change in colonic epithelium ([@b47-bt-26-335]; [@b21-bt-26-335]; [@b28-bt-26-335]). Therefore, female sex hormones may play a protective role in the development of colon cancer, by decreasing the level of bile acid ([@b47-bt-26-335]; [@b23-bt-26-335]).

SEX DIFFERENCES IN EFFICACY AND TOXICITY OF CHEMOTHERAPY
========================================================

Sex-related differences at the genetic and molecular levels also affect the differences in the degree of drug response ([@b72-bt-26-335]). Although sex disparities in the incidence and mortality of cancer have been observed for a variety of cancers, chemotherapy has been conducted independent of sex ([@b36-bt-26-335]; [@b5-bt-26-335]; [@b79-bt-26-335]). Research involving animal model and clinical trials has been almost male-oriented. Accumulating evidence supports sex-related response to chemotherapeutic agents. Anticancer drugs, which represent sex differences in efficacy and toxicity, are summarized and listed in [Table 1](#t1-bt-26-335){ref-type="table"}.

5-FU
----

In the treatment of various cancers, 5-FU has been widely used as an effective chemotherapy ([@b43-bt-26-335]). 5-FU as a pyrimidine antagonist inhibits thymidine synthase which is essential for DNA synthesis ([@b60-bt-26-335]; [@b77-bt-26-335]; [@b43-bt-26-335]). It has been observed that 5-FU might elicit different toxicities depending on sex ([@b67-bt-26-335]; [@b66-bt-26-335]). Clearance of 5-FU is higher in male (179 l/h/m^2^) than in female (155 l/h/m^2^) ([@b49-bt-26-335]). Low clearance of 5-FU in females can result in higher toxicity ([@b72-bt-26-335]). Dihydropyrimidine dehydrogenase (DPD) breaks down 5-FU ([@b73-bt-26-335]; [@b15-bt-26-335]; [@b43-bt-26-335]). DPD plays a crucial role in toxicity associated with 5-FU chemotherapy ([@b29-bt-26-335]). The activity of DPD was decreased in female and the difference in DPD activity between males and females is 15% ([@b20-bt-26-335]). A lower DPD activity associated with toxicity in women might be attributed to DPD deficiency syndrome ([@b50-bt-26-335]). Reduced degradation of 5-FU in female influences therapeutic efficacy and toxicity ([@b45-bt-26-335]). In 5-FU-based chemotherapy, women experimented higher toxicities, including stomatitis, leukopenia, alopecia, and diarrhea, more frequently and severely than men ([@b66-bt-26-335]).

Paclitaxel
----------

Antitumor effects of paclitaxel, which inhibits depolymerization of cytoskeletal microtubules, interfere with cell division ([@b61-bt-26-335]; [@b35-bt-26-335]). It was reported that female patients with solid tumors have 20% lower elimination of paclitaxel than male patients ([@b34-bt-26-335]). Peripheral compartments of female (0.83 mmol/l) are saturated at lower plasma concentrations compared with those of male (1.74 mmol/l) ([@b34-bt-26-335]). On the other hand, paclitaxel elimination is faster in male (≤0.5 h) than in female (≤1 h) ([@b34-bt-26-335]). In the treatment with paclitaxel combined with carboplatin, the number of female patients exhibiting toxicity such as severe leukopenia was greater than that of male patients ([@b76-bt-26-335]; [@b62-bt-26-335]). Conversely, female patients diagnosed with lung carcinoma (5.3 months) who were treated with paclitaxel combined with carboplatin showed longer median progression-free survival (PFS) rate than male patients (4.4 months) ([@b76-bt-26-335]). These sex-related differences might be explained by DNA repair, which was lower in females than in males ([@b74-bt-26-335]). The lower DNA repair ability might affect tumor cell in female after administering cytotoxic anticancer drug and influence the prolonged PFS in female patients ([@b76-bt-26-335]).

Doxorubicin
-----------

Doxorubicin is an anthracycline DNA-damaging agent that targets the topoisomerase 2 activity and DNA intercalation ([@b27-bt-26-335]; [@b57-bt-26-335]; [@b51-bt-26-335]). Another predicted mechanism of doxorubicin generates free radicals resulting in damage to membrane and DNA of cancer cell ([@b27-bt-26-335]; [@b57-bt-26-335]; [@b51-bt-26-335]). In patients with breast cancer or lymphoma, male with normal liver function showed significantly higher doxorubicin clearance (59 l/h/m^2^) than female (27 l/h/m^2^) ([@b17-bt-26-335]). Female might be an independent risk factor increasing the toxicity of doxorubicin such as cardiac abnormalities ([@b41-bt-26-335], [@b42-bt-26-335]). Exposure to doxorubicin in childhood leukemia in females increases the risk of early cardiotoxicity compared with in males ([@b42-bt-26-335]). P-glycoprotein, which is expressed by multidrug resistance protein 1 gene, is a drug transporter that pumps many foreign substances out of cells ([@b63-bt-26-335]). Expression of p-glycoprotein in males is 2-fold higher than in females ([@b63-bt-26-335]). In females, doxorubicin and doxorubicinol, which is a doxorubicin metabolite, accumulate following a reduced expression of p-glycoprotein and leads to cardiotoxicity ([@b71-bt-26-335]).

Disparities in drug metabolizing enzymes between men and women might have an impact on drug metabolism or volume of distribution of doxorubicin ([@b26-bt-26-335]; [@b39-bt-26-335]; [@b42-bt-26-335]). Doxorubicin is not accumulated at a higher concentration in adipose tissue ([@b58-bt-26-335], [@b42-bt-26-335]). The higher proportion of fat in female patients might lead to a higher concentration of doxorubicin in non-adipose tissues such as heart in women even if men and women carried the same body surface areas.

Cisplatin
---------

Cisplatin as *cis*-diamminedichloroplatinum (II) exhibits covalent bonding with adjacent guanines located in the major groove of DNA ([@b6-bt-26-335]). This intra-strand cross-links with DNA result in distortion of DNA and antitumor effects. Female patients treated with cisplatin-based therapy show substantially higher toxicities such as vomiting and nausea than males ([@b40-bt-26-335]). Male rats treated with cisplatin show general toxicity, prolonged thermal latency and slow motor nerve conduction velocity than female rats ([@b75-bt-26-335]). Sex-dependent difference may not be related to lower body size in females but physiological variables such as distinct body composition and metabolic activity ([@b75-bt-26-335]). In the Yoruban population which comprised of African descent, male-derived cell lines demonstrated higher sensitivity to cisplatin than female-derived cell lines ([@b32-bt-26-335]). The half-maximal inhibitory concentration (IC~50~) of cisplatin in male-derived cell lines was lower than that in female-derived cell lines ([@b32-bt-26-335]).

Bevacizumab
-----------

Bevacizumab is a monoclonal antibody, which blocks vascular endothelial growth factor and inhibits angiogenesis in tumors ([@b24-bt-26-335]; [@b59-bt-26-335]). It was reported that clearance of bevacizumab was 26% higher in male patients with solid tumors than in female patients, which is associated with a greater muscle mass in males than in females ([@b44-bt-26-335]). Chemotherapy with bevacizumab for non-small cell lung cancer led to more severe hypertension and neutropenia and higher rate of abdominal pain in female patients than in male patients ([@b11-bt-26-335]).

Rituximab
---------

Rituximab is a monoclonal antibody, which targets CD20 on B cell surface. It is used to treat autoimmune diseases and hematological cancers such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The clearance of rituximab is higher in male patients (8.21 ml/h) with DLBCL than in female patients (12.68 ml/h) and the elimination half-life in male patients (t~1/2β~=30.7 days) is longer compared with female patients (t~1/2β~=24.7 days) ([@b52-bt-26-335]). In the DLBCL treatment with rituximab, the better treatment outcomes were more prominent in females than in males ([@b56-bt-26-335]). GSTT1 deletion might be related to adverse prognosis only in DLBCL male patients who are treated with rituximab ([@b13-bt-26-335]). Also, in the treatment with rituximab, male patients had a worse PFS than female patients both in DLBCL and in follicular lymphoma ([@b56-bt-26-335]).

CONCLUSIONS
===========

The present review highlights the importance of sex differences in the epidemiology and chemotherapy of cancer. Evidence supports sex differences in efficacy and toxicity to anticancer drugs based on individual pharmacokinetics and pharmacodynamics. Data suggest that sex influences pathophysiology, clinical signs, treatment outcome and response in cancer. Sex is a crucial factor in predicting chemotherapy outcome, with implications for therapeutic efficacy and toxicity. Our review provides supporting information for appropriate chemotherapy based on sex. Based on the plethora of studies reporting potential sex differences in cancer, cancer research and therapy should be considered specifically to enhance patient outcomes. Sex difference in cancer susceptibility can be used to develop a causal hypothesis for the disease, or to define subgroups at the highest risk for preventive action. Sex plays a crucial role in improving individual pharmacogenomics and in developing personalized therapeutic medicines. Pharmacogenomic differences between the sexes might play a significant role in chemotherapy in the future. Further studies are needed to provide greater insight into sex differences in cancer and improve treatment outcomes with anticancer agents.
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Anticancer drugs with sex differences in efficacy and toxicity

  Drug             Sex differences                                                                                                                          References
  ---------------- ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  5-fluorouracil   Clearance is higher in males than in females                                                                                             [@b49-bt-26-335]
                   Females experienced higher toxicity (including stomatitis, leukopenia, alopecia and diarrhea) frequently and severely than males         [@b66-bt-26-335]
  Paclitaxel       Females showed lower elimination than males                                                                                              [@b34-bt-26-335]
                   Peripheral compartment of females is saturated at lower plasma concentrations levels compared with males                                 [@b34-bt-26-335]
                   Elimination is faster in males than in females                                                                                           [@b34-bt-26-335]
                   Females experienced severe leukopenia greater than males                                                                                 [@b62-bt-26-335]; [@b76-bt-26-335]
                   Females showed longer median progression-free survival than males                                                                        [@b76-bt-26-335]
  Doxorubicin      Males have significantly higher clearance than females                                                                                   [@b17-bt-26-335]
                   Females experienced higher risk of early cardiotoxicity than males following treatment with doxorubicin in childhood leukemia            [@b42-bt-26-335]
  Cisplatin        Females experienced higher toxicities including vomiting and nausea than males                                                           [@b40-bt-26-335]
                   Male rats showed prolonged heat latency and slower motor nerve conduction than female rats                                               [@b75-bt-26-335]
                   The half-maximal inhibitory concentration (IC~50~) of male cell lines was lower than that of females                                     [@b32-bt-26-335]
  Bevacizumab      Clearance was higher in males than in females                                                                                            [@b44-bt-26-335]
                   Female experienced more severe hypertension and neutropenia, and higher rate of abdominal pain than males                                [@b11-bt-26-335]
                   Females experienced higher rates of abdominal pain than males                                                                            [@b11-bt-26-335]
  Rituximab        Clearance was higher in males than in female                                                                                             [@b52-bt-26-335]
                   Half-life of elimination in male was longer compared with females                                                                        [@b52-bt-26-335]
                   The better responses from treatment and outcomes were more prominent in females than in males                                            [@b56-bt-26-335]
                   Male patients had a worse progression-free survival than female patients both in diffuse large B-cell lymphoma and follicular lymphoma   [@b56-bt-26-335]
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